Lexeo Therapeutics, Inc. (LXEO) earnings
LXEO earnings moved a median of +0.62% by the close. Quarterly and annual LXEO reports and results, each read against the price at its own news timestamp. Back to the LXEO overview →
22 measured LXEO earnings events.
Where these LXEO earnings landedvs 22 measured LXEO earnings reactions
| Middle 50% of LXEO earnings reactions | -5.74% to +4.45% |
|---|---|
| Median reaction (to close) | +0.62% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 LXEO earnings events with a measured close landed between -5.74% and +4.45%; 55% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Lexeo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.14% | +0.62% | |
| Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | -1.14% | +0.62% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +3.17% | +2.00% | |
| Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | +3.17% | +2.00% | |
| Form 10-K Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -1.54% | -2.05% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.73% | -0.85% | |
| Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights | Press release | -0.73% | -0.85% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.33% | +5.04% | |
| Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights | Press release | +1.33% | +5.04% | |
| Form 10-Q/A Lexeo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -3.75% | +1.12% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +5.48% | -5.74% | |
| Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights | Press release | +5.48% | -5.74% | |
| Form 10-K Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +8.70% | +36.79% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +9.83% | -11.68% | |
| Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results | Press release | +9.83% | -11.68% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +4.45% | |
| Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights | Press release | +0.00% | +4.45% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +7.89% | |
| Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights | Press release | +0.00% | +7.89% | |
| Form 10-K Lexeo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -3.06% | -8.75% | |
| Form 10-Q Lexeo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | -0.99% | -8.27% | |
| Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights | Press release | -0.99% | -8.27% |
Keep exploring
More LXEO: analyst actions → · SEC filings → · LXEO overview →